Evidence map›Paper›PMID 34740942›Full record

ReviewBMJ open respiratory research2021

Improving the early identification of COVID-19 pneumonia: a narrative review.

Daniel Goyal, Matthew Inada-Kim, Fatam Mansab, Amir Iqbal, Brian McKinstry, Adeeb P Naasan, Colin Millar, Stephen Thomas, Sohail Bhatti, Daniel Lasserson and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in BMJ open respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Daniel GoyalDepartment of Acute Internal Medicine, Gibraltar Health Authority, Gibraltar, Gibraltar daniel.goyal@gha.gi.ORCID 0000-0003-0418-8859
Matthew Inada-KimDepartment of Infection, Antimicrobial Resistance and Deterioration, NHS England, Redditch, Worcestershire, UK.
Fatam MansabDepartment of Public Health, Gibraltar Health Authority, Gibraltar, Gibraltar.
Amir IqbalDepartment of Covid-19 Remote Monitoring of Patients During Response & Recovery, NHS Grampian, Aberdeen, Aberdeen, UK.
Brian McKinstryUsher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
Adeeb P NaasanDepartment of General Medicine, Islands Hospital, Oban, UK.
Colin MillarDepartment of General Medicine, Islands Hospital, Oban, UK.
Stephen ThomasDepartment of Respiratory Medicine, Raigmore Hospital, Inverness, Highland, UK.
Sohail BhattiDepartment of Public Health, Gibraltar Health Authority, Gibraltar, Gibraltar.
Daniel LassersonHospital at Home, Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, UK.
Derek BurkeDepartment of Clinical Governance, Gibraltar Health Authority, Gibraltar, Gibraltar.
Gibraltar Health Authority · GIHampshire Hospitals NHS Foundation Trust · GBNHS Grampian · GBRaigmore Hospital · GBUniversity of Edinburgh · GBUniversity of Warwick · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Delayed presentation of COVID-19 pneumonia increases the risk of mortality and need for high-intensity healthcare. Conversely, early identification of COVID-19 pneumonia grants an opportunity to intervene early and thus prevent more complicated, protracted and less successful hospital admissions. To improve the earlier detection of COVID-19 pneumonia in the community we provide a narrative review of current evidence examining the clinical parameters associated with early disease progression. Through an evolving literature review, we examined: the symptoms that may suggest COVID-19 progression; the timing of deterioration; the utility of basic observations, clinical examination and chest X-ray; the value of postexertion oxygen saturations; and the use of CRP to monitor disease progression. We go on to discuss the challenges in monitoring the COVID-19 patient in the community and discuss thresholds for further assessment. Confusion, persistent fever and shortness of breath were identified as worrying symptoms suggestive of COVID-19 disease progression necessitating urgent clinical contact. Importantly, a significant proportion of COVID-19 pneumonia patients appear not to suffer dyspnoea despite severe disease. Patients with this asymptomatic hypoxia seem to have a poorer prognosis. Such patients may present with other signs of hypoxia: severe fatigue, exertional fatigue and/or altered mental status. We found duration of symptoms to be largely unhelpful in determining risk, with evidence of deterioration at any point in the disease. Basic clinical parameters (pulse, respiratory rate, blood pressure, temperature and oxygen saturations (SpO

Indexed as

COVID-19HumansHypoxiaRisk AssessmentSARS-CoV-2Treatment OutcomeCOVID-19pneumoniarespiratory infection

Identifiers

PMID34740942
PMCPMC8573292
OpenAlexW3208573307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.